menu
    • menu

    Company profile for PentixaPharm

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals that specifically target the CXCR4-receptor expressed in most fast-progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    PentixaPharmGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Bismarckstraße 13 97080 Würzburg
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://pentixapharm.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/pentixapharm/?trk=public_post_share-update_actor-image
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pentixapharm Expands CXCR4 Radiopharma Platform With New Data
    Pentixapharm Expands CXCR4 Radiopharma Platform With New Data

    06 Oct 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-10-06/pentixapharm-highlights-expanding-cxcr4-radiopharmaceutical-platform-with-new-clinical-findings-at-e

    PHARMAWEB
    06 Oct 2025
    Share Share
    Pentixapharm Advances PentixaTher To 4th Dose In AML Trial
    Pentixapharm Advances PentixaTher To 4th Dose In AML Trial

    26 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-26/pentixapharm-announces-advancement-of-pentixather-to-fourth-dose-level-in-acute-myeloid-leukemia-tr

    PHARMAWEB
    26 Sep 2025
    Share Share
    Pentixapharm Reports EUR 14M Loss Including Risk Provisions
    Pentixapharm Reports EUR 14M Loss Including Risk Provisions

    24 Jan 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-01-24/pentixapharm-holding-ag-closes-the-2024-financial-year-with-a-loss-of-eur-14-million-including-risk

    PHARMAWEB
    24 Jan 2025
    Share Share
    Pentixapharm Gets EUR 6.77M For Glycotope-Developed Assets
    Pentixapharm Gets EUR 6.77M For Glycotope-Developed Assets

    07 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/07/3005124/0/en/Pentixapharm-Receives-EUR-6-77-Million-for-Intangible-Assets-Formerly-Developed-by-Glycotope.html

    GLOBENEWSWIRE
    07 Jan 2025
    Share Share
    First Patient Treated in Ph I/II of Lu177-PentixaTher for Leukemia
    First Patient Treated in Ph I/II of Lu177-PentixaTher for Leukemia

    21 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/21/2984987/0/en/First-Patient-Treated-in-Phase-I-II-Trial-in-Acute-Myeloid-and-Acute-Lymphoblastic-Leukemia-with-Lu177-PentixaTher-Expanding-the-Evidence-Base-for-Targeted-Radiotherapy-Approach.html

    GLOBENEWSWIRE
    21 Nov 2024
    Share Share
    Pentixapharm scores $22M in IPO to advance radiopharma trials
    Pentixapharm scores $22M in IPO to advance radiopharma trials

    03 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pentixapharm-scores-22m-frankfurt-ipo-push-ahead-clinical-stage-radiopharmaceuticals

    FIERCE BIOTECH
    03 Oct 2024
    Share Share

    ABOUT THIS PAGE

    Contact PentixaPharm and get a quotation

    PentixaPharm is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Pentixafor bulk with DMF offered by PentixaPharm

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search